Related Experiment Video

Updated: Aug 8, 2026

Visualization and Quantification of Mesenchymal Cell Adipogenic Differentiation Potential with a Lineage Specific Marker
13:26

Visualization and Quantification of Mesenchymal Cell Adipogenic Differentiation Potential with a Lineage Specific Marker

Published on: March 31, 2018

[Heart fatty-acid binding protein (h-FABP): a new cardiac marker]

A Servonnet1, H Delacour, C Dehan

  • 1Laboratoire de biochimie, pharmacologie, toxicologie cliniques, Hôpital d'Instruction des Armées Robert Picqué, Villenave d'Ornon. a_servonnet@yahoo.fr

Annales De Biologie Clinique
|May 16, 2006
PubMed

Insights

Heart Fatty-Acid Binding Protein (h-FABP) aids in diagnosing heart attacks. This biomarker is released during ischemia, offering rapid detection of myocardial injury and reperfusion.

Area of Science:

  • Cardiology
  • Biomarker Discovery
  • Clinical Diagnostics

Background:

  • Heart Fatty-Acid Binding Protein (h-FABP) is a cytosolic protein primarily found in the heart.
  • Elevated h-FABP levels in circulation indicate cardiac ischemia or injury.
  • h-FABP has shown potential in assessing acute myocardial infarction and reperfusion.

Purpose of the Study:

  • To review the clinical utility of h-FABP in detecting myocardial injury.
  • To evaluate the strengths and weaknesses of h-FABP as a cardiac biomarker.
  • To discuss the application of rapid h-FABP assays in clinical practice.

Main Methods:

  • Review of existing studies on h-FABP in cardiology.
  • Analysis of h-FABP's role in diagnosing acute myocardial infarction.
  • Evaluation of rapid immuno-chromatographic assays for h-FABP detection.

Main Results:

  • h-FABP is released into circulation following cardiac ischemia.
  • Studies suggest h-FABP's value in excluding myocardial infarction and detecting reperfusion.
  • Rapid assays provide results within 15 minutes, facilitating timely diagnosis.

Conclusions:

  • h-FABP is a promising biomarker for myocardial injury.
  • Its rapid detection offers significant advantages in acute cardiac care.
  • Further evaluation of h-FABP's strengths and limitations is warranted.

More Related Videos

Quantification of Endothelial Fatty Acid Uptake using Fluorescent Fatty Acid Analogs06:03

Quantification of Endothelial Fatty Acid Uptake using Fluorescent Fatty Acid Analogs

Published on: August 15, 2025

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...